The research report offers insights into both existing and therapeutics under development for the treatment of gram-negative bacterial infection.
Albany, NY -- (SBWIRE) -- 02/09/2017 -- The emergence and proliferation of highly resistant gram-negative bacteria is a major concern given the limited number of antimicrobial agents that are currently available to combat these organisms. The abundant and often inappropriate use of antibiotics is further contributing to the emergence of these organisms. This is creating a pressing need for reliable and effective therapeutics for the treatment of gram-negative bacterial infection. Therefore, the rising research and development activities coupled with increasing investments are driving the global gram-negative bacterial infection market.
Request a Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=94
The research report offers insights into both existing and therapeutics under development for the treatment of gram-negative bacterial infection. It explores the investments in the pipeline, existing practices, and the latest clinical developments pertaining to the global gram-negative bacterial infection market. It also presents a detailed description of the competitive landscape of the market.
Global Gram-negative Bacterial Infection: Infection-type Segmentation
On the basis of type of infection, the global gram-negative bacterial infection market can be segmented into wound or surgical site infections, pneumonia, urinary tract infections, bloodstream infections, and meningitis. Pneumonia is the most common disease caused gram-negative bacteria followed by urinary tract infections. According to a report by the World Health Organization (WHO), this disease killed 920 136 children under the age of 5 in 2015. Meningitis is also a common disease caused by these organisms. A study conducted by one of the key players in the market, Merck & Co. Inc., indicates that about 25% of the newborns who suffer from gram-negative bacteria induced meningitis die and 15% to 20% of the infants develop serious brain and nerve problems such as enlargement of ventricles, deafness, cerebral palsy, and mental retardation. The alarming rate of mortality and morbidity due to these organisms is escalating the growth of the market.
Request for TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=94
Global Gram-negative Bacterial Infection: Analysis of Treatment Options
In terms of treatment, the global gram-negative bacterial infection market can be divided into Carbapenems, Colistin, Tigecyclin, Sulbactam, Doxycycline, and Rifampin. The demand for carbapenes is high for the treatment of gram-negative bacterial infections, particularly pneumonia. Some of the most commonly used carbapenes for the treatment of pneumonia are meropenem, imipenem, and doripenem. Sulbactam is majorly used for treatment of meningititis. However, colistin, tigecyclin, doxycycline, and rifampin are used for treating every type of gram-negative bacterial infection and are, therefore, likely to be adopted more in the long run.
Read Complete Report @ https://www.tmrresearch.com/gram-negative-bacterial-infection-market
Global Gram-negative Bacterial Infection: Competitive Landscape
Players in the global gram-negative bacterial market are primarily focusing on development of more effective drugs. To put this in perspective, Prokarium Ltd. has developed Typhetec for the treatment of gram-negative bacterial infections. Currently, the drug is under phase II clinical trials and on the basis of phase I results, market experts predict that this drug will be beneficial for the treatment of gram-negative bacterial infections in future and will encourage the growth of the market. Some of the key players in the market are Baxter International Inc., Sanofi-Aventis, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Nektar Therapeutics, Dainippon Sumitomo Pharma Co., Ltd., Rib-X Pharmaceuticals, Inc. and Targeted Genetics Corporation.
About TMR Research
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todayâ€™s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clientsâ€™ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.
Our savvy custom-built reports span a gamut of industries such as pharmaceuticals, chemicals and metals, food and beverages, and technology and media, among others. With actionable insights uncovered through in-depth research of the market, we try to bring about game-changing success for our clients.